Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Mar-Apr;23(2):482-487.

Cytoreduction and HIPEC for peritoneal carcinomatosis of pancreatic cancer

Antonios-Apostolos Tentes  1 , Nicolaos Pallas, Christina Karamveri, Dimitrios Kyziridis, Christos Hristakis
Affiliations
  • PMID: 29745096

Cytoreduction and HIPEC for peritoneal carcinomatosis of pancreatic cancer

Antonios-Apostolos Tentes et al. J BUON. 2018 Mar-Apr.

Abstract

Purpose: Peritoneal carcinomatosis of pancreatic cancer is generally considered for palliative treatment. The purpose of this study was to report the outcome of cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in patients with pancreatic cancer and peritoneal carcinomatosis.

Methods: Patients with documented resectable peritoneal carcinomatosis of pancreatic cancer underwent cytoreductive surgery in combination with HIPEC from 2008-2016 by the same surgical team.

Results: Six patients underwent 8 cytoreductions. Complete or near-complete cytoreduction was possible in 7 cases, and palliative surgery in one case. Gemcitabine was used in 5 cases during HIPEC, and cisplatin+mitomycin-C in 2 others. All patients received adjuvant chemotherapy with gemcitabine. Four patients survived without evidence of recurrence for more than 12 months.

Conclusions: Cytoreductive surgery with HIPEC may be considered a treatment option in highly selected patients with pancreatic cancer and peritoneal carcinomatosis.

PubMed Disclaimer

MeSH terms